brigatinib

01/01/2017 - "Brigatinib effective in ALK-positive non-small-cell lung cancer."
09/01/2019 - "An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer."
08/01/2019 - "Materials & methods: The ALTA trial, an open-label, Phase II, randomized dose-comparison study, evaluated the safety and efficacy of brigatinib in ALK+ non-small-cell lung cancer. "
01/01/2022 - "Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients."
01/01/2022 - "Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients."

12/01/2020 - "Approval was based on results from a randomized, dose-ranging phase II study (ALK in Lung Cancer Trial of AP26113 (ALTA)). "
01/01/2019 - "Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer."
01/01/2017 - "The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers."
11/01/2019 - "Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient."
03/30/2022 - "Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study."

01/01/2022 - "Brigatinib is a second-generation ALK inhibitor effective in presence of several ALK mutations with demonstrated activity against central nervous system metastases. "
04/10/2020 - "This study provides critical information to clinicians regarding the efficacy of brigatinib for ALK-p, ALK-inhibitor-naïve, advanced NSCLC patients, with and without CNS metastasis. "
01/01/2023 - "As cell migration is a critical step during metastasis, we assessed the anti-migratory activities of several clinical ALK inhibitors in NSCLC cells and observed differential anti-migratory capabilities despite similar ALK inhibition, with brigatinib displaying superior anti-migratory effects over other ALK inhibitors. "
12/29/2022 - "Complete response of skull metastasis was confirmed after brigatinib treatment (90 mg daily). "
02/01/2021 - "Although final analysis data are awaited with interest, brigatinib therapy extends the first-line treatment options available for standard of care in this patient population, including patients with CNS metastases."

12/01/2021 - "The suggested survival benefit with brigatinib in patients with brain metastases warrants future study."
04/01/2022 - "Brigatinib was the less expensive, with a cost of 269.78 € for each month of PFS for both intention-to-treat (ITT) population that patients with baseline brain metastases (BBM). "
12/01/2021 - "Posthoc analyses suggested an overall survival benefit for brigatinib in patients with baseline brain metastases (HR = 0.43, 95% CI: 0.21-0.89). "
06/28/2021 - "In this exploratory prospective phase II clinical trial, newly diagnosed ALK+ NSCLC patients will be randomized into two treatment arms, stratified by presence of brain metastases and ECOG performance status: brigatinib (experimental arm) vs. any other approved second-generation ALK TKI. "
01/01/2020 - "Brigatinib yielded a longer progression-free survival, a higher objective response rate, and greater effectiveness against brain metastases-and was less detrimental to patients' quality of life."

01/01/2022 - "Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation."
01/01/2020 - "Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement."
01/01/2021 - "Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report."
01/01/2021 - "Vorinostat combined with brigatinib significantly improved EGFR-TKI sensitivity to EGFR C797S by inducing EGFR-dependent cell death and may be a promising therapy in treating C797S-resistant lung adenocarcinomas."
01/01/2020 - "Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy."